Sarepta Therapeutics Inc
SRPT
Market Cap$3.7B
Close$
$153.22
306% upside
Current Fair Value
306% upsideUndervalued by 306% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.70 Billion |
|---|---|
| Enterprise Value | $4.92 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $2.34 |
| Beta | 0.84 |
| Outstanding Shares | 97,362,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -14.74 |
|---|---|
| PEG | 1.1 |
| Price to Sales | 1.72 |
| Price to Book Ratio | 3.43 |
| Enterprise Value to Revenue | 2.2 |
| Enterprise Value to EBIT | -25.14 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 1.29 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Sarepta Therapeutics Inc
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...